Pieris Pharmaceuticals

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. Pieris has established a diverse pipeline of Anticalin therapeutics for a number of different indications and has R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group and others. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
Boston, US
Size (employees)
38 (est)
Pieris Pharmaceuticals was founded in 2001 and is headquartered in Boston, US

Pieris Pharmaceuticals Office Locations

Pieris Pharmaceuticals has office in Boston
Boston, US

Pieris Pharmaceuticals Metrics

Pieris Pharmaceuticals Summary

Market capitalization

$112 m

Closing share price

Pieris Pharmaceuticals's current market capitalization is $112 m.

Pieris Pharmaceuticals Financials

Pieris Pharmaceuticals's revenue is $2.9 m in FY, 2015 which is a 45.4% decrease from the previous period.
FY, 2014FY, 2015


$5.4 m$2.9 m

Revenue growth, %


Net Income

($9.8 m)($14.1 m)

Pieris Pharmaceuticals Market Value History

Pieris Pharmaceuticals News

Pieris Pharmaceuticals Company Life

You may also be interested in